Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer
Year: 2016
Type: conference-abstract
Source: Cancer Research
Authors: JK Litton, JL Blum, Y-H Im, M Martin, L Mina, H Roché, F Visco, X Yang, NA Lokker, DL Lounsbury, W Eiermann
Institutions: The University of Texas MD Anderson Cancer Center, Samsung Medical Center, Hospital General Universitario Gregorio Marañón, Institut universitaire du cancer de Toulouse Oncopole, National Cancer Coalition, Indiana University Indianapolis, Indiana University School of Medicine, BioMarin (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2395647884